ONCR Projected Dividend Yield

Oncorus Inc ( OTCBB : ONCR )

Oncorus is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. Co.'s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, Co.'s main product candidate, is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A, or CVA21, encapsulated within an lipid nanoparticle. Co. is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus, or SVV. Both CVA21 and SVV have extensive clinical experience and safety profiles when administered IV.

11 YEAR PERFORMANCE RESULTS